Prostamax
Prostamax is a synthetic tetrapeptide bioregulator with the sequence KEDP (Lys-Glu-Asp-Pro), developed within the Khavinson family of short peptides. It has been investigated in cell and animal models for its tissue-specific effects on prostate cells, with reported activity on chromatin organization and gene expression modulation relevant to urological research.
$66.99
Prostamax - Prostate-Targeted Peptide Bioregulator
Investigated for selective nuclear uptake and DNA binding within prostatic epithelial cell models
Studied for direct binding to histone complexes and CpG-rich DNA regions in cultured nuclei
Reported to influence transcription of genes linked to epithelial differentiation and maturation
Observed to relax condensed chromatin domains and reactivate silenced regions in aged cell nuclei
Preclinical models suggest normalized secretory activity and improved structural organization of glandular tissue
In vitro work indicates modulation of cell cycle markers relevant to age-associated glandular remodeling studies
Research models report reduced pro-inflammatory cytokines and enhanced antioxidant enzyme expression in target tissue
Khavinson peptide studies explore restoration of aged tissue parameters, senescence pathways and telomere dynamics
Description
Prostamax is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), developed within the Khavinson family of short peptide bioregulators. It is studied for its ability to interact with chromatin and modulate tissue-specific gene expression in experimental models, particularly those involving prostate tissue.
In cell and animal studies, Prostamax has been observed to bind selectively to DNA regions and influence transcription of genes associated with cellular differentiation, proliferation balance, and tissue homeostasis. Research models have reported effects on prostatic epithelial cell activity, including modulation of secretory function and histological markers related to age-associated tissue changes.
Additional investigations have focused on its geroprotective and epigenetic properties, with observations of reduced oxidative stress markers and improved cellular viability in aged tissue preparations. These findings place Prostamax within the broader category of short-chain peptide bioregulators studied for site-directed chromatin interactions.
Supplied as a ready-to-use injection pen (2 mL solution, 1 click = 0.01 mL) for subcutaneous research administration, Prostamax is intended exclusively for in vitro and preclinical research applications.
Clinical Status:
Prostamax is a research peptide bioregulator evaluated primarily in Eastern European preclinical and limited observational studies focused on prostate tissue bioregulation and geroprotection. It is not approved for medical use and remains restricted to experimental and laboratory research.
Evidence type:
Human RCT ☐ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory ☐
Mechanism of Action
Prostamax (KEDP) is a short tetrapeptide bioregulator proposed to act through site-specific binding to DNA and histone proteins, modulating chromatin structure and gene expression in prostate-derived cells. In research models, KEDP has been reported to regulate transcription of genes involved in cellular differentiation, proliferation, and apoptosis within prostate tissue. This epigenetic-type mechanism distinguishes Khavinson peptides from receptor-mediated signaling and is studied for its tissue-selective regulatory effects.
Benefits
- Prostate Tissue-Specific Regulation:
Prostamax (KEDP) is a Khavinson-type tetrapeptide bioregulator studied for its selective affinity toward prostate tissue. Research models suggest it penetrates cell nuclei and interacts with specific DNA regions, modulating gene expression linked to prostatic epithelial cells. This tissue-specific action has made KEDP a central subject in bioregulator research focused on organ-targeted peptide signaling. - Chromatin Modulation and Gene Expression:
Experimental studies indicate that KEDP interacts directly with chromatin and histone complexes, influencing the transcription of genes involved in cellular differentiation and proliferation. By binding to CpG-rich DNA sequences, Prostamax has been observed to regulate expression patterns associated with prostate cell maturation, a mechanism of interest in epigenetic peptide research. - Heterochromatin Decondensation:
A hallmark observation in Khavinson bioregulator research is KEDP-induced heterochromatin decondensation in cultured cells. By relaxing condensed chromatin domains, Prostamax has been reported to reactivate silenced gene regions in aged nuclei, a mechanism central to studies of epigenetic reprogramming and tissue-specific transcriptional recovery. - Support for Prostatic Epithelial Function:
In preclinical investigations, KEDP has been reported to normalize secretory activity of prostatic epithelial cells and support structural integrity of the glandular tissue. Research models of age-related prostatic changes have shown improved cellular organization and reduced markers of tissue dysfunction following KEDP administration. - Cell Proliferation Research Observations:
Prostamax has been studied for its potential influence on cell proliferation dynamics within prostatic tissue. In vitro models suggest modulation of proliferation markers and improved cell cycle regulation, making it a candidate of interest in research exploring age-associated prostatic changes and glandular remodeling. - Inflammation and Oxidative Stress Modulation:
Research models have observed that KEDP may reduce local inflammatory markers and oxidative stress indicators within prostatic tissue. This modulatory effect is linked to downregulation of pro-inflammatory cytokines and improved antioxidant enzyme expression, supporting its investigation in models of age-related glandular inflammation and tissue aging. - Age-Related Tissue Regeneration:
As part of the Khavinson peptide family, Prostamax is extensively studied for its role in geroprotective research. Animal studies suggest that short peptide bioregulators like KEDP may restore functional parameters of aged tissues, supporting investigations into cellular senescence, telomere dynamics, and organ-specific longevity mechanisms. - Low Molecular Weight and Bioavailability:
With a molecular weight of ~487.5 g/mol and a compact KEDP sequence, Prostamax demonstrates favorable penetration across cellular membranes in experimental settings. This small-peptide profile allows efficient delivery into target tissues and nuclei, making it a practical research tool for studying short bioregulator peptides and their epigenetic mechanisms.
Research Data
| Study / Model | Reported effect |
|---|---|
| Aged rat prostate tissue | ↑ Expression of tissue-specific genes; restored secretory epithelium morphology |
| Cultured prostate epithelial cells | Modulation of chromatin structure and heterochromatin decondensation |
| Rodent models of aged prostate tissue | ↓ Age-related glandular changes; improved histological architecture |
| In vitro cell proliferation assays | Regulation of proliferative activity in prostate-derived cell lines |
| Aging-related gene expression studies | ↑ Transcription of genes associated with prostate function and differentiation |
| Comparative peptide bioregulator research | Tissue-specific activity confined to prostate cells, consistent with KEDP targeting |
Stack Suggestions
Prostamax (KEDP) is often combined in research with:
- Prostamax + Epitalon → Explores tissue-specific regulation alongside systemic telomere and pineal pathway modulation in aging models.
- Prostamax + Thymalin → Pairs prostate-targeted bioregulation with thymic peptide activity for broader immunoregulatory research.
- Prostamax + Vesugen → Combines tetrapeptide bioregulators to study chromatin remodeling and vascular tissue effects.
- Prostamax + BPC-157 → Investigated for complementary tissue regeneration and anti-inflammatory signaling in experimental models.
⚠ Stacks are for experimental design only; not safety or efficacy guidance.
Pen Dosage Chart
| Prostamax Pen 20 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
Dosage & Protocols Variations
Standard bioregulator course
- Dose: 1 mg (10 clicks)
- Duration: 20 days
- Frequency: Once daily, subcutaneous (SubQ) with the pen
- Cycle Interval: 1-2 courses per year, about 6 months apart
- Pen Coverage: 1 pen = 20 days
- Goal / Description: Bioregulator research on chromatin and tissue-specific effects in cell and animal models. Basis: derived from a published or patent dose range; not a validated human dose.
Intensive short course
- Dose: 2 mg (20 clicks)
- Duration: 10 days
- Frequency: Once daily, subcutaneous (SubQ) with the pen
- Cycle Interval: 1-2 courses per year, about 6 months apart
- Pen Coverage: 1 pen = 10 days
- Goal / Description: Shorter, higher-dose bioregulator course for the same research models. Basis: derived from a published or patent dose range; not a validated human dose.
Bioregulator stack with Testagen 5 mg
- Dose: 1 mg (10 clicks) + 0.25 mg Testagen (Testagen Pen 5 mg: 10 clicks)
- Duration: 20 days
- Frequency: Once daily, subcutaneous (SubQ) with the pen
- Cycle Interval: 1-2 courses per year, about 6 months apart
- Pen Coverage: 1 pen = 20 days
- Goal / Description: Parallel course of two Khavinson-type bioregulators in organ-specific research models. Basis: vendor/community convention only; no published dosing study.
Possible Side Effects
Prostamax (KEDP) is generally well-tolerated in available preclinical research.
Reported observations are limited and mild:
- No significant toxicity reported in available cell and animal studies at tested concentrations.
- Occasional transient local reactions at injection sites in animal models.
- Short-chain tetrapeptides of this class are generally non-immunogenic in experimental settings.
No evidence of systemic, hormonal, or organ-specific adverse effects has been documented in the available Khavinson tetrapeptide literature. Long-term safety data in humans is not established, and the compound remains restricted to experimental and laboratory research.
Product Attributes
- CAS #: N/A
- Molecular Formula: C20H33N5O9
- Sequence (AA): KEDP
- Molecular Weight: ~487.5 g/mol
- PubChem CID: 9848296
- Half-Life: N/A (not established)
- Synonyms: KEDP, Lys-Glu-Asp-Pro, H-Lys-Glu-Asp-Pro-OH
- Type: Synthetic research peptide (tetrapeptide bioregulator)
- Research Focus: Khavinson-type tetrapeptide bioregulator (KEDP) studied for chromatin and tissue-specific effects in cell and animal models
Scientific References
- Effects of short peptides on lymphocyte chromatin in senile subjects In vitro
- The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ In vitro
- Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) In vitro
- Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters In silico
- Peptide Regulation of Gene Expression: A Systematic Review Review
- PubChem CID 9848296 (Prostamax) Registry
- Patent EP1353939B1 / WO2002066497A2 (Khavinson VKh, Malinin VV, Grigoriev EI) Patent
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™: precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1-8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6-8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
